select trial semaglutide results Full Affirm CV Risk Reduction With in Nondiabetics Pivotal Results for Semaglutide in

There is no high-quality evidence documenting menstrual cycle alterations as a recognized adverse effect of semaglutide (Wegovy)

### Funding Statement SDL and AC were supported by the National Science Foundation (Grant Nos.\ CAREER DMS-1944574 and DMS-2325258) ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained

See how RYBELSUS performed in the PIONEER 3 Trial

Sacubitril/valsartan has demonstrated consistent benefits not only in HF with reduced ejection fraction (HFrEF) but also in selected patients with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF), especially women and those with borderline left ventricular ejection fraction, as shown in the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) and Prospective Comparison of ARNI with ARB Global Outcomes in HF With Preserved Ejection Fraction (PARAGON-HF) trials and supported by Indian ARNI PRESERVED study

Una de las grandes ventajas del protocolo para bajar de peso con inhibidores del aGLP-1, que aplico en mi consulta, es que trabajamos con un laboratorio que incluye un programa de nutricin personalizado, sin costo adicional para el paciente.

If you've ever wondered whether GLP-1s are right for you—or felt confused by the endless noise online—this episode brings the conversation back to center